Clinical Trials Browser

Phase 2 × Gliosarcoma × 1 year × Clear all

NCT04817254 2026-03-18

Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

Phase 2 Active not recruiting

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT02455557 2026-02-25

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Phase 2 Active not recruiting

66 enrolled 11 charts

Glioblastoma, Gliosarcoma

NCT07301268 2026-02-03

GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma

Phase 2 Suspended

Astrocytoma, Glioblastoma, Gliosarcoma

NCT05465954 2026-01-12

Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Phase 2 Recruiting

Glioblastoma, Gliosarcoma

NCT03746080 2025-11-14

Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Phase 2 Completed

21 enrolled 12 charts

Glioblastoma, Glioma, Gliosarcoma

NCT02337686 2025-08-15

Pembrolizumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Active not recruiting

18 enrolled 12 charts

Glioblastoma, Gliosarcoma

NCT01931098 2025-08-11

Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab

Phase 2 Completed

35 enrolled 13 charts

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

NCT03137888 2025-08-03

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

Phase 2 Completed

30 enrolled 12 charts

Glioblastoma, Gliosarcoma

NCT03197506 2025-04-06

Pembrolizumab and Standard Therapy in Treating Patients With Glioblastoma

Phase 2 Active not recruiting

Glioblastoma, Gliosarcoma